Peptides that stimulate subcutaneous adipogenesis
AssigneeThe Regents of the University of California
InventorsEva A. Turley, Seyed Bahram Bahrami, Mina J. Bissell
Life of this patent
Estimating the term…
Abstract
Peptides of 5 to 14 amino acids in length that stimulate subcutaneous adipogenesis and uses thereof are provided.
Claims26
A pharmaceutical or cosmetic composition comprising a pharmaceutically or cosmetically acceptable carrier and a modified peptide or peptidomimetic, wherein the modified peptide or peptidomimetic is at least 6 amino acids in length, but not more than 8 amino acids in length, and comprises a motif having the sequence:
- KSEVSK (SEQ ID NO:
- 3), wherein the modified peptide:
- comprises a protecting group, wherein the modified peptide has improved ex vivo and/or in vivo peptide stability and/or improved skin penetration when administered topically, relative to an unmodified peptide of the same sequence;
- or
- is functionalized with a polymer selected from the group consisting of a polyethylene glycol, a cellulose, and a modified cellulose, wherein the modified peptide has increased bioavailability, relative to an unmodified peptide of the same sequence;
- and
- wherein the peptidomimetic comprises one or more peptide linkages replaced with a linkage selected from the group consisting of —CH2NH—, —CH2S—, —CH2—CH2—, —CH═CH—, —COCH2—, —CH(OH)CH2—, and —CH2SO, wherein the peptidomimetic has an improvement in a property, relative to an unmodified peptide of the same sequence, wherein the property is selected from the group consisting of:
- economy of production, chemical stability, half-life, absorption, potency, efficacy, and/or reduced antigenicity.
A modified peptide or peptidomimetic of at least 6 amino acids in length, but not more than 8 amino acids in length, comprising a motif having the sequence:
- KSEVSK (SEQ ID NO:
- 3), wherein the modified peptide:
- comprises a protecting group, wherein the modified peptide has improved ex vivo and/or in vivo peptide stability and/or improved skin penetration when administered topically, relative to an unmodified peptide of the same sequence;
- or
- is functionalized with a polymer selected from the group consisting of a polyethylene glycol, a cellulose, and a modified cellulose, wherein the modified peptide has increased bioavailability, relative to an unmodified peptide of the same sequence;
- and
- wherein the peptidomimetic comprises one or more peptide linkages replaced with a linkage selected from the group consisting of —CH2NH—, —CH2S—, —CH2—CH2—, —CH═CH—, —COCH2—, —CH(OH)CH2—, and —CH2SO, wherein the peptidomimetic has an improvement in a property, relative to an unmodified peptide of the same sequence, wherein the property is selected from the group consisting of:
- economy of production, chemical stability, half-life, absorption, potency, efficacy, and/or reduced antigenicity.
Dependencies are inferred from the claim text.